As wearable healthcare monitoring systems advance, there is immense potential for biological sensing to enhance the management of type 1 diabetes (T1D). The aim of this work is to describe the ongoing development of biomarker analytes in the context of T1D. Technological advances in transdermal biosensing offer remarkable opportunities to move from research laboratories to clinical point‐of‐care applications. In this review, a range of analytes, including glucose, insulin, glucagon, cortisol, lactate, epinephrine, and alcohol, as well as ketones such as beta‐hydroxybutyrate, will be evaluated to determine the current status and research direction of those analytes specifically relevant to T1D management, using both in‐vitro and on‐body detection. Understanding state‐of‐the‐art developments in biosensing technologies will aid in bridging the gap from bench‐to‐clinic T1D analyte measurement advancement.

中文翻译：

---

1 型糖尿病背景下生物标志物的综述：增强血糖控制的生物传感

随着可穿戴医疗保健监测系统的进步，生物传感在加强 1 型糖尿病 (T1D) 管理方面具有巨大潜力。这项工作的目的是描述 T1D 背景下生物标志物分析物的持续开发。透皮生物传感技术的进步为从研究实验室转向临床护理点应用提供了绝佳的机会。在这篇综述中，将评估一系列分析物，包括葡萄糖、胰岛素、胰高血糖素、皮质醇、乳酸、肾上腺素和酒精，以及酮类，如β-羟基丁酸，以确定这些分析物的当前状态和研究方向与 T1D 管理相关，使用体外和体内检测。了解生物传感技术的最先进发展将有助于缩小从实验室到临床 T1D 分析物测量进步的差距。